Mallinckrodt Aims To Nix Medicaid FCA Suit Over Acthar Gel
Law360 (July 13, 2020, 4:08 PM EDT) -- The government is wrongly conflating fraud with a regulatory disagreement, Mallinckrodt ARD LLC told a Massachusetts federal court Monday, urging a judge to toss False Claims Act claims centering on its pricey H.P. Acthar Gel drug, which treats infantile spasms and other conditions.
The U.K.-based company, which acquired the drug when it bought Questcor Pharmaceuticals Inc. in 2014 for $5.6 billion, argued in a motion to dismiss that nowhere in the government's case does it establish that it committed fraud, an essential element of the underlying claim.
The Centers for Medicare & Medicaid Services claim Mallinckrodt has shorted the U.S. government...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!